On July 18, 2025, the U.S. Food and Drug Administration (FDA) took decisive action against Sarepta Therapeutics following the deaths of three individuals who had received the company’s gene therapy…
The United States FDA has awarded Fast Track Designation to the investigational drug AVB-S6-500 for the potential treatment of platinum-resistant recurrent ovarian cancer. You can find out more detailed information…
In late September, Food and Drug Administration designated "fast track" status to the research and development of CPP-1X/sul for adults diagnosed with Familial Adenomatous Polyposis (FAP). Overseeing the project are Cancer…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
